We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Biodiagnostics System Tests Patients for Different Disease Targets

By LabMedica International staff writers
Posted on 29 Jun 2009
A biodiagnostic system simultaneously tests patients for different disease targets, on-site in a laboratory, community hospital, or in a doctor's office, in less than an hour.

The nanoparticle-based system can detect very low concentrations of molecules associated with disease; a technology that has the potential to transform the future of medical diagnostics and patient point-of-care.

Chad Mirkin, Ph.D., the George B. More...
Rathmann professor of chemistry and director of the International Institute for Nanotechnology at Northwestern University (Evanston, IL, USA) invented the nanoparticle-based diagnostic system that can detect very low concentrations of molecules associated with disease.

Nanosphere commercialized many of the nanoparticle-based, medical diagnostic assays built upon the principles of Dr. Mirkin's inventions. This led to the development of the Verigene Id system. The platform enables simple, cost-effective, and highly sensitive genomic and proteomic testing on a single platform.

The Lemelson-Massachusetts Institute of Technology (MIT; Cambridge, MA, USA) US$500,000 prize was awarded to Dr. Mirkin, cofounder and member of the board of directors of Nanosphere and NanoInk, companies that develop and commercialize advanced molecular diagnostics systems. The Lemelson-MIT Prize recognizes individuals who transform their ideas into inventions and innovations that improve the world. The prize was awarded on June 25, 2009 at MIT.

When Dr. Mirkin received the award he commented, "The world doesn't want just another way. It wants a better way."

Related Links:
The Lemelson-Massachusetts Institute of Technology Program
International Institute for Nanotechnology at Northwestern University



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
POC Immunoassay Analyzer
Procise DX
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image Credit: Adobe Stock

Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals

Many diseases begin developing years before symptoms emerge, making early detection difficult for healthcare systems and clinical laboratories. Linking molecular changes with longitudinal health data could... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.